Tags : OTC

Takeda to Divest OTC and Select Non-core Assets to Celltrion

Shots: Takeda has signed an agreement with Celltrion to divest 18 select OTC and prescription pharmaceutical assets exclusively commercialized in the Asia Pacific under which Takeda will receive $266M as up front in cash and up to $12M as milestones. The transaction is expected to be closed in H2’20 Additionally, the two companies signed manufacturing […]Read More

STADA Acquires GSK’s Consumer Healthcare Portfolio to Expand its OTC

Shots: STADA to acquire GSK’s 15 well-established consumer healthcare brands including Venoruton, for venous treatment, Coldrex cold remedy, Cetebe vitamin C supplements, Mebucaine sore throat range and Tavegyl allergy brand The acquisition will strengthen STADA’s OTC portfolio and accelerates its growth in European countries. The transaction is expected to be completed in Q2’2020 The acquisition […]Read More

Zentiva to Acquire Alvogen’s Generics and OTC Business in Central

Shots: Zentiva acquires Alvogen’s CEE market consisting of 200+ generics and OTC therapies across multiple therapeutics areas which include brands like Lactacyd, Persen, EuBiotic. The transaction is expected to be closed in Q1’20 The focus of the acquisition is to combine two leading branded generics and OTC business in the CEE region and will strengthen […]Read More

STADA to Acquire GSK’s OTC Portfolio for the Expansion of

Shots: STADA acquires GSK’s six brands containing five skin care/topical application and one pediatric cough remedy namely Oilatum, Eurax, Savlon Antiseptic Cream, Ceridal, Tixylix and Polytar. The transaction is expected to close in Aug 2019 The focus of the acquisition is to strengthen and expand STADA’s Consumer Health business in European Healthcare markets. Additionally, the […]Read More